Cancer adapts. It hides. It resists. But we are learning its tricks! Even patients with the same diagnosis can respond completely differently to treatment. Why? Our team is uncovering the answers.

The mission of our group is to advance cancer research, by integrating biomarker identification with novel technologies, with an impact on the development of immunotherapeutic strategies. We're uncovering why some tumours evade immune attack and how to make them visible again.

The identification and characterisation of novel biomarkers is relevant for the improvement of diagnosis, prognosis, and treatment of cancers.

Using advanced imaging and spatial technologies, we're mapping the hidden battleground where cancer and the immune system collide. We analyse tissue biopsies at the molecular level to identify biological fingerprints that explain varied patient responses and prognosis.

We partner with hospitals and pharmaceutical companies worldwide, turning laboratory insights into real-world life-saving discoveries.

Your generosity through donations funds advanced equipment, reagents, and student-led research, enabling earlier detection and personalised treatments for cancers.

https://www.ucl.ac.uk/medical-sciences/divisions/cancer/centres-and-networks/cancer-immunotherapy-accelerator/immune-onco-pathology

UCLH Fund Reference: 1477 (Teresa Marafioti)